[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623549":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":56,"collaborators":10,"id":59,"slug":10,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Integrative Cure Stay Group",null,"Participants attend a 7-day integrative oncology retreat including individualized consultations, complementary therapies, and group-based mind-body interventions.",[13],"Behavioral: Integrative Cure Stay",{"label":15,"type":10,"description":16,"interventionNames":17},"Matched Control Group","Participants receive usual oncology follow-up without attending the retreat.",[18],"Other: Matched Control Group",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"BEHAVIORAL","Integrative Cure Stay","Participants attend a 7-day integrative oncology retreat including individualized consultations, complementary therapies, and group-based mind-body interventions",[9],{"type":6,"name":15,"description":26,"armGroupLabels":27,"otherNames":10},"Participants receive usual oncology follow-up without attending the retreat",[15],[29],{"name":30,"affiliation":31,"role":32},"Viola Heinzelmann-Schwarz, Prof. MD","University Hospital of Basel","STUDY_CHAIR",[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Isabell Ge, MD","CONTACT","+41 61 32 85885","Isabellxiang.ge@usb.ch",[40],{"facility":41,"status":42,"city":43,"state":10,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"University Hospital Basel","RECRUITING","Basel","4031","Switzerland",{"type":47,"coordinates":48},"Point",[49,50],7.57327,47.55839,{"lat":50,"lon":49},[53,54],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},{"name":35,"role":55,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":55,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Isabell Xiang Ge","Dr. med.","100623549",false,"NCT07398079","Pilot Observational Study of an Integrative Cure Stay Program","Via Shalva","Inclusion Criteria:\n\n* Breast and gynecological cancer (including but not limited to ovarian, endometrial, cervical, vulvar and vaginal cancer) survivors, including recurrent disease\n* Completed primary treatment (operation +\u002F- radiation +\u002F- chemotherapy)\n* Age ≥ 18 years\n* Ongoing or planned maintenance treatment scheduled for \\> 3 months during study period is allowed (e.g. antihormonal therapy, Anti-Her2-antibodies, CDK4\u002F6-inhibitors, Anti-VEGF-inhibitor, PARP-inhibitor, immune-checkpoint inhibitors etc.)\n* Signed informed consent for participation of the trials\n* Presence of a stoma is allowed\n* Prior cancer is allowed\n* Prior treatment - including chemotherapy - for a prior malignant tumor (including breast or gynecological cancer) is allowed\n* Concomitant participation in an experimental therapeutic drug trial is allowed\n* Use of other complementary methods (including mistletoe) is allowed\n* Pregnancy is allowed.\n\nExclusion Criteria:\n\n* Language or cognitive deficits (including impaired consciousness) that are incompatible with the participation in the study\n* Severe physical or psychiatric comorbidity that prevents a patient from participating in the study\n* Patients incapable of giving consent","FEMALE","18 Years",{"count":68,"type":69},30,"ESTIMATED","OBSERVATIONAL","This pilot observational study evaluates the feasibility and acceptability of conducting a prospective study alongside the individualized integrative oncology cure stay program \"Via Shalva\" for breast and gynecological cancer survivors. The study further explores preliminary changes in patient-reported outcomes, physiological measures, and biological markers before and after the retreat and compared with a matched control group.",[73,74],"Breast Cancer","Gynecologic Cancer",[76,77,78],"Complementary Therapies","Integrative Medicine","Feasibility Studies","2026-05-19",{"date":81,"type":82},"2026-05-22","ACTUAL",{"date":84,"type":82},"2025-10-06",{"date":86,"type":69},"2027-06",{"name":5,"class":6},1]